Trial Number

017-20

Condition

Stroke

Participant Age Range

45 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

ARCADIA-CSI (Cognition and Silent Infarcts)

Post-stroke cognitive decline and dementia pose a significant public health problem. The risk of dementia is more than doubled after stroke, and over 2 million American stroke survivors sufferfrom dementia. Silent (or ‘covert’) infarcts are likely an important cause of cognitive decline in stroke survivors, particularly in patients at high risk for cardioembolism. This notion is supported by studies that describe a relationship between atrial fibrillation and incidentdementia, studies demonstrating that patients with cardioembolic stroke are at greatest risk of cognitive decline5, and studies showing that anti-coagulation reduces the occurrence of infarcts and cognitive decline in stroke survivors with atrial fibrillation. The evidence suggesting that silent infarcts caused by cardioembolism plays an important role in the development of post-stroke cognitive decline prompted the design of ARCADIA-CSI, anancillary study to the ARCADIA trial, that will test if treatment with apixaban is an effective strategy to prevent silent infarcts and preserve cognitive function in patients with stroke of unknown cause and atrial cardiopathy.

Provider

Related Clinical Trials

Click on the category you are interested in.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
Are you a current MemorialCare patient?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.